Back to Search
Start Over
Faecal Myeloperoxidase as a Biomarker of Endoscopic Activity in Inflammatory Bowel Disease.
- Source :
-
Journal of Crohn's & colitis [J Crohns Colitis] 2022 Dec 05; Vol. 16 (12), pp. 1862-1873. - Publication Year :
- 2022
-
Abstract
- Background and Aims: Inflammatory bowel disease [IBD], consisting of Crohn's disease [CD] and ulcerative colitis [UC], is a relapsing-remitting illness. Treat-to-target IBD management strategies require monitoring of gastrointestinal inflammation. This study aimed to investigate faecal myeloperoxidase [fMPO], a neutrophil granule enzyme, as a biomarker of IBD activity.<br />Methods: Prospectively recruited participants with IBD, undergoing ileocolonoscopy for disease assessment, provided biological samples and completed symptom questionnaires prior to endoscopy. fMPO, C-reactive protein [CRP], and faecal calprotectin [fCal] were compared with validated endoscopic indices [simple endoscopic score for CD and UC endoscopic index of severity]. Receiver operating characteristic [ROC] curves assessed the performance of fMPO, CRP, and fCal in predicting endoscopic disease activity. Baseline biomarkers were used to predict a composite endpoint of complicated disease at 12 months [need for escalation of biologic/immunomodulator due to relapse, steroid use, IBD-related hospitalisation, and surgery].<br />Results: A total of 172 participants were recruited [91 female, 100 with CD]. fMPO was significantly correlated with endoscopic activity in both CD [r = 0.53, p < 0.01] and UC [r = 0.63, p < 0.01], and with fCal in all patients with IBD [r = 0.82, p < 0.01]. fMPO was effective in predicting moderate-to-severely active CD [AUROC 0.86, p < 0.01] and UC [AUROC 0.92, p < 0.01]. Individuals with a baseline fMPO > 26 µg/g were significantly more likely to reach the composite outcome at 12 months (hazard ratio [HR] 3.71, 95% confidence interval [CI] 2.07-6.64, p < 0.01).<br />Conclusions: Faecal myeloperoxidase is an accurate biomarker of endoscopic activity in IBD and predicted a more complicated IBD course during follow-up.<br /> (© The Author(s) 2022. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation.)
- Subjects :
- Female
Humans
Biomarkers metabolism
C-Reactive Protein metabolism
Chronic Disease
Endoscopy, Gastrointestinal
Feces chemistry
Leukocyte L1 Antigen Complex metabolism
Peroxidase metabolism
Severity of Illness Index
Male
Colitis, Ulcerative diagnosis
Colitis, Ulcerative metabolism
Crohn Disease diagnosis
Crohn Disease metabolism
Inflammatory Bowel Diseases diagnosis
Inflammatory Bowel Diseases metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1876-4479
- Volume :
- 16
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- Journal of Crohn's & colitis
- Publication Type :
- Academic Journal
- Accession number :
- 35803583
- Full Text :
- https://doi.org/10.1093/ecco-jcc/jjac098